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HIGH-THROUGHPUT DRUG SCREEN TO IDENTIFY COMPOUNDS 
 
WORKING SELECTIVELY AND SYNERGISTICALLY WITH CQ 
 
TO INHIBIT PROLIFERATION OF TSC2-DEFICIENT CELLS  
	
ANDRES F. SANIN 
 
ABSTRACT 
Tuberous sclerosis complex (TSC) is a multisystem genetic disease that is caused 
by a germ line mutation in the genes TSC1 and TSC2. Patients with the disease tend to 
suffer from benign tumors of the brain, heart, kidneys, skin, and other organs that contain 
giant cells. Although mTORC1 inhibitors (rapamycin and rapalogs) are often used to 
treat TSC because of their efficacy in promoting tumor shrinkage, clinical studies in the 
past have shown that when treatment is taken away, the tumor size returns to its original 
state.  
The objective of this study was to identify compounds that selectively inhibit 
proliferation of TSC2-deficient cells. A high-throughput screen of about 4000 
compounds was performed using a lysosomal inhibitor (chloroquine [CQ], 5 μM) and a 
“repurposing” library of compounds. Through some yet to be determined mechanism, the 
combination of ritanserin (a selective serotonin reuptake inhibitor [SSRI]) and 
chloroquine was found to synergize to selectively inhibit the cell viability of DJK MEFs 
and TSC2-/-KO cells (TFFs) starting at 48 hours after treatment. The effects of this 
combination treatment were confirmed in a second cell line (TFFs) exhibiting similar 
		
		 vii 
reduction in proliferation. Interestingly, treatment with CQ (5 μM) and ritanserin (20 μM) 
showed synergistic action (combination index [CI] = 0.6) against TSC2-deficient cells. 
This combination treatment induced apoptosis (41%) in TSC2-deficient cells but not in 
TSC2-expressing cells. These results suggest a novel treatment approach in tuberous 
sclerosis complex and provide an incentive for further investigation of the mechanisms 
contributing to the vulnerability of TSC2-deficient cells. Moreover, the use of an already 
Food and Drug Administration (FDA)-approved compound can lead to a more rapid 
pharmacologic approach for TSC patients. 																										
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INTRODUCTION 
 
 Tuberous sclerosis complex (TSC) is a multisystem genetic disease that is caused 
by a germline mutation in the genes TSC1 and TSC2 (Henske, Jóźwiak, Kingswood, 
Sampson, & Thiele, 2016). The majority of individuals with TSC have a de novo 
germline mutation in either TSC1 or TSC2 without any prior history of TSC. Patients 
with the disease tend to suffer from benign tumors of the brain, heart, kidneys, skin, and 
other organs that contain giant cells (Figure 1). TSC is responsible for 1/6000 births, and      
Figure 1. Phenotypic manifestations of tuberous sclerosis complex. This diagram shows the most 
commonly affected systems and their associated lesions. The percentages represent the approximate 
incidence in patients with TSC. LAM = lymphangioleiomyomatosis; MMPH = Multi Micronodular 
Pneumocyte Hyperplasia; SEGA = Subependymal Giant Cell Astrocytoma; SEN = Subependymal 
Nodules; TAND = TSC-Associated Neuropsychiatric Disorder. Figure taken from (Henske et al., 2016).  
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symptoms of the disease tend to affect the central nervous system, including seizures, 
mental retardation, epilepsy, autism, kidney problems, and skin lesions (Henske, Jóźwiak, 
Kingswood, Sampson, & Thiele, 2016). Epilepsy may be the most prevalent and 
challenging clinical manifestation of TSC, with a prevalence of 70%-80% patients having 
virtually all subtypes of seizures (simple partial, complex partial, and generalized tonic-
clonic seizures) (Crino, Nathanson, & Henske, 2006).  
The diagnosis for TSC is sometimes difficult but is frequently suspected with 
signs found on inspection of the skin. The diagnosis criteria for TSC consists of a set of 
major and minor diagnostics features (Table 1) (Henske, Jóźwiak, Kingswood, Sampson, 
& Thiele, 2016). Cases that meet these criteria fulfill a clinical diagnosis of TSC. Further 
genetic testing can be done of the TSC1 or TSC2 loci, although this is viewed as 
corroborative (Crino, Nathanson, & Henske, 2006). The onset of the disease is age 
dependent, with many lesions appearing at certain ages and other hamartomas (dysplastic 
cells) appearing during fetal life and disappearing later. For example, cortical tubers and 
cardiac rhabdomyomas form during embryogenesis and are common findings in infants 
suffering from TSC (Crino, Nathanson, & Henske, 2006). In about 10% of patients with 
TSC, the growth of subependymal giant-cell tumors can cause obstruction of 
cerebrospinal fluid flow, hydrocephalus, increased intracranial pressure, and even death 
(Figure 2) (Crino, Nathanson, & Henske, 2006). However, in about 15% of patients who 
meet the criteria for a diagnosis of TSC (Table 1), there are no identifiable mutations. 
These patients tend to have milder clinical disease (i.e., a lower incidence of mental 
retardation, seizures, and dermatologic signs), compared with patients having the TSC1 
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or TSC2 mutations (Henske, Jóźwiak, Kingswood, Sampson, & Thiele, 2016). TSC 
appears to follow the Knudson two-hit tumor-suppressor gene model because the 
inactivation of both alleles of either TSC1 or TSC2 seems to be required for lesion 
formation (Cooney, 2014). Treatment for the disease varies from case to case as the 
tumors tend to grow in different places in different patients. Although 
mammalian/mechanistic target of rapamycin complex 1 (mTORC1) inhibitors 
(rapamycin and rapalogs) promote tumor shrinkage, clinical studies in the past have 
shown that when treatment is taken away, the tumor size returns to its original state 
(Campbell, Franks, Borne, Shin & Zhang 2018) Thus, there is a definite need for 
developing novel approaches toward decreasing tumor size in TSC patients. 
Figure 1. Dermatologic, renal, and pulmonary manifestations of TSC. A) 4-year-old patient with facial 
angiofibromas; B) 8-year-old patient; C) 21-year-old patient. D) Resected kidney distorted by many 
angiomyolipomas. Sections stained with hematoxylin and eosin show fat (arrow) and smooth muscle (E) 
and aberrant vessels (F). G) Tomography of lungs shows presence of lymphangiomyomatosis. H) Smooth 
muscle proliferation in lymphangiomyomatosis. H) immunohistochemical labeling with muscle specific 
actin. TSC = Tuberous Sclerosis Complex. Figure taken from (Crino, Nathanson, Henske, 2006). 
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Table 1. Diagnostic Criteria for Tuberous Sclerosis Complex (TSC)  
 aTable taken from (Crinio, Nathanson, & Henske 2006). 
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Mutations in genes TSC1 and TSC2 that encode for hamartin and tuberin proteins, 
respectively, are associated with the development of TSC. Only one gene (TSC1/2) needs 
to be affected for the onset of TSC to occur. The TSC proteins function as a part of a 
larger biochemical pathway to regulate mTORC1 by directly inhibiting the GTPase, Rheb 
(Krymskaya & McCormack, 2017). Rheb (Ras homolog enriched in brain), a member of 
the Ras superfamily, is a specific GTPase downstream of TSC that functionally links the 
TSC1-TSC2 complex to the mammalian/mechanistic target of rapamycin (mTOR) 
pathway (Crino, Nathanson, & Henske, 2006). The pathway (Figure 3) works by 
activation of a serine-threonine kinase, protein kinase B (Akt), which phosphorylates 
TSC (a complex of two proteins), releasing the GTPase Rheb from TSC suppression and 
activating mTORC1(Krymskaya & McCormack, 2017). TSC2 itself is a GAP (GTPase-
activating protein) for Rheb. mTORC1 is involved in many biological processes, 
including protein biosynthesis by phosphorylating the protein kinase p70S6K and the 
translational inhibitor 4E-BP. These and other downstream targets of mTOR are 
associated with many biological processes (e.g., cell growth, autophagy, proliferation, 
angiogenesis, lipid synthesis, and mRNA splicing, transcription). (Krymskaya & 
McCormack, 2017). The pathway itself is only active for a brief period of time to ensure 
that there is no uncontrolled cell growth and proliferation. Inactivation of both alleles of 
TSC1/2 can lead to hyperactivation of the mTORC1 pathway, inducing uncontrolled cell 
growth and proliferation (Cooney, 2014).  
	6 
 
 
Figure 2. Schematic representation of the mTOR signaling pathway and the role of TSC1/2. This 
diagram shows that Akt phosphorylates TSC, releasing GTPase Rheb from TSC suppression, resulting in 
activation of mTORC1. AMPK = AMP-Activated Protein Kinase; Akt = Protein Kinase B; Figure taken 
from (Krymskaya & McCormack, 2017). 
 A progression of TSC is the formation of lymphangioleiomyomatosis (LAM), a 
rare lung disease that affects almost exclusively women. About 40% of girls with TSC 
also go on to develop LAM in their childbearing years (Cooney, 2014). LAM is 
characterized by multiple thin-walled cystic lesions, and as a metastasizing neoplasm, 
LAM spreads by means of the lymphatics and ultimately targets the lungs. All pulmonary 
structures tend to become infiltrated with benign spindle and epithelioid cells that express 
smooth-muscle and melanocyte-lineage markers and harbor mTOR-activating mutations 
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in TSC genes (Krymskaya & McCormack, 2017). As in the case of TSC, LAM is caused 
by inactivating mutations in the TSC genes, resulting in hyperactivation of mTORC1 
(Cooney, 2014). Women without TSC can also develop LAM (sporadic form). These 
women carry mutations only in the TSC2 gene and only in their tumor cells (Crino, 
Nathanson, Henske, 2006). Approximately 60% of these patients have renal 
angiomyolipoma. In patients that have both sporadic LAM and angiomyolipoma, 
identical TSC2 mutations have been identified in both abnormal kidney and lung cells but 
not in normal cells. The presence of identical mutations suggests that both cells are 
genetically related and most likely arise from a common progenitor cell (Crino, et al., 
2006). This has led to the “benign metastasis” hypothesis for the pathogenesis of 
lymphangioleiomyomatosis, which states that benign cells with TSC1 or TSC2 mutant 
cells may have the ability to travel to the lungs from angiomyolipomas in the kidney 
(Crino, et al., 2006).  
 After the discovery of TSC, the link between TSC and mTOR quickly led to the 
discovery of rapamycin as a natural product that can block the mTOR pathway and shrink 
kidney tumors in women with LAM (Cooney, 2014). Although this was not a cure-all 
treatment, the discovery of rapamycin led to other discoveries, including the role of 
estrogen in promoting the survival and metastatic spread of LAM-like smooth muscle 
cells to the lung. This has allowed the development of therapies such as the SAIL 
(Sirolimus and Autophagy Inhibition in LAM) trial. The problem with rapalogs (or 
rapamycin analogs) is that the moment the treatment is taken away, the tumors tend to 
progress back to their cancerous state.  
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One issue with the treatment of TSC is the multitude of manifestations that the 
cancer presents. Many patients have angiomyolipomas, and these TSC-related neoplastic 
tumors contain a high proportion of abnormal blood vessels and as a result, have a high 
risk of rupture and hemorrhage (Crino, Nathanson, Henske, 2006). Many growing 
angiolipomas respond to a treatment with sirolimus (also known as rapamycin) or 
everolimus. In clinical trials, this rapamycin educed angiomyolipoma lesion size by about 
30% during a 12-month treatment. This volumetric reduction was not sustained as tumors 
showed regrowth to at least their original state, revealing that the drug has a cytostatic 
effect but lacks a cytotoxic effect. Patients receiving sirolimus are currently being treated 
for an indefinite amount of time that may be lifelong (Franz, & Capal, 2017).  
Although there is currently no cure for TSC, the hyperactivity of mTORC1 that is 
involved in patients with a missing TSC1/2 gene presents several opportunities for 
potential treatments. One way that researchers are looking to find possible cancer 
inhibitors is by performing a high-throughput drug screen (Medvetz, et al., 2014). This 
method allows for the discovery of molecules that can heighten the cytotoxicity of 
currently known mTORC1 inhibitors. For example, ritanserin is a serotonin receptor (or 
5-hydroxytryptamine receptor [5-HTR]) antagonist that has been used in clinical studies 
in the treatment of a variety of syndromes related to anxiety and depression. Previous 
studies have demonstrated that ritanserin has off-target effects and can therefore work 
through a serotonin-independent mechanism (Campbell, et al., 2018). Specifically, these 
targets include inhibition of diacylglycerol kinase-alpha (DGK-a), FER tyrosine kinase, 
and c-RAF (Franks, Campbell, Purow, Harris, et al., 2017). In particular, the inhibition of 
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c-RAF by ritanserin could prove to be a potential mechanism of treatment for TSC. c-
RAF is involved in the mitogen-activated protein kinase (MAPK) pathway that regulates 
cellular responses to external signals (Franks, et al., 2017) Specific growth factors and 
ligands cause the activation of RAS GTPase, which furthermore activates RAFs (A-RAF, 
B-RAF, and c-RAF) by recruitment to the cellular membrane. The activated RAFs can 
phosphorylate and activate the downstream effectors MAPK/ERK kinase (MEK) and 
then extracellular signal-regulated kinase (ERK) to control cell proliferation, apoptosis, 
differentiation, and migration in cancer (Dominguez, et al., 2013). More specifically, c-
RAF and has two direct downstream targets, B-cell lymphoma 2 (Bcl-2) and Bcl-2-
associated death promoter (BAD). Both of these proteins, when activated by c-RAF, 
cause the release of cytochrome c in the mitochondria and cause the inhibition of 
apoptosis. Although ritanserin may potentially have several off-target effects, this could 
allow for higher development of resistance mechanisms.  
 Because of the enhanced system of interconnected molecular pathways involving 
mTOR and TSC, combination techniques could provide more efficacy than single-agent 
approaches. Combination therapies exploit the chance of targeting different parts of the 
mTOR pathway and can reduce the development of drug resistance. The antimalarial 
drug, chloroquine (CQ), is promising for cancer treatment. Several clinical trials are in 
progress that show favorable effects of CQ as a novel antitumor reagent. Although the 
precise mechanism is unknown, the anti-autophagic activity of CQ seems to be 
contributing to its anticancer effects. Chloroquine has been shown to inhibit autophagy 
by suppressing lysosomal proteases and preventing autophagosome-lysosome fusion 
	10 
 
events (Filippakis, et al., 2017). Chloroquine crosses the lysosomal membrane and 
becomes protonated, which causes its accumulation within the cell (Filippakis, et al., 
2017). The continuous sequestration causes the normally acidic pH in the lysosome to 
rise, thereby inactivating lysosomal enzymes. Previous studies have demonstrated that 
CQ can be an effective single agent in breast cancer treatment (Fukuda, Oda, Wada-
Hiraike, Sone, Inaba, et al., 2015). Other studies have found that CQ in combination with 
other drugs may be used as a potent anticancer treatment. In particular, work by Datta et 
al. (2019) indicated that the use of CQ pretreatment can be a strategy to combat lung 
cancer metastasis (Datta, Choudhury, Das, Mukherjee, Dasgupta et al., 2019). Although 
CQ was shown to be effective in certain cancers, the precise mechanism by which CQ 
induces cell death is still not yet understood.  
 One possible mechanism of CQ that has been investigated recently is its role in 
autophagy. Autophagy plays a crucial role in the survival of cancer cells, and certain 
autophagy inhibitors are being evaluated as possible strategies in the treatment of cancer. 
Chloroquine is a known antimalarial drug that is also used as an inhibitor of autophagy. 
Previous studies have shown that CQ treatment induces caspase-dependent apoptosis in 
vitro (Masud et al., 2016). The function of CQ is to inhibit autophagy in vitro and in vivo 
by suppressing lysosomal proteases and preventing autophagosome-lysosome fusion 
events (Masud et al., 2016). Several researchers have examined the effect of CQ 
treatment on cancer cells with little success, but other studies have proven that CQ with 
other drugs in combination therapy may be used as a potent anticancer agent.  
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Goals of the Present Study 
 The present study focuses on using a high-throughput drug screen to find 
compounds that synergize with chloroquine (a known autophagy inhibitor) to selectively 
inhibit the proliferation of TSC2 null cells. The cells are used as a model of the tumors 
that develop in the brain, heart, kidney, and lung of individuals with tuberous sclerosis 
complex (TSC), an autosomal dominant tumor suppressor gene disorder.  
 To show that the resulting drug hits are selective for TSC2 null cells only, the 
study uses cell viability assays to demonstrate that certain drugs, such as ritanserin, have 
a selective effect on TSC2-/- cells and not on TSC2+/+ cells. To show synergy between a 
specific drug and chloroquine, the study applies the Loewe Additivity model to determine 
whether the use of chloroquine enhances the efficacy of the identified compounds that 
were previously used as single agents. The study also sets out to find the mechanism of 
the drug combination that selectively inhibits the proliferation of TSC2 null cells. The 
discovery of this mechanism can help in better understanding combination therapy and in 
deciding whether these drugs can be used for patient treatment.   
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METHODS 
Cell Lines and Culture Conditions  
TSC2-/- p53 and TSC2 +/+ p53-/- mouse embryonic fibroblasts (MEFs) were 
provided by David James Kwiatkowski (DJK) (Brigham and Women’s Hospital, Boston, 
MA, USA). In addition, MEFs were isolated from TSC2flox/flox-Rosa26-CreERT2 embryos 
and clones with knockout of TSC2 (TSC2 KO MEFs). Cells treated with ethanol were 
used as controls (TSC2 WT MEFs). Cells treated with 4-hydroxytamoxifen (4-HT; 2 μM) 
for 4 days induced TSC2 loss (TSC2 KO MEFs). Cells were grown in 4.5 g/L glucose-
containing Dulbecco’s Modified Eagle Medium (DMEM; Gibco/Thermo Fisher 
Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; 
Atlanta Biologicals, Flowery Branch, GA, USA) and were kept in a humidity-controlled 
incubator at 37 oC and 5% CO2. 
 
Materials 
The CellTiter-Glo (CTG) reagent was obtained from Promega Corporation 
(Madison, WI, USA). Ritanserin and chloroquine were purchased from Tocris Bioscience 
(Minneapolis, MN, USA). Apo-ONE assay kits were bought from Promega Corporation. 
The DGK-α antibody was purchased from Proteintech Group, Inc. (Rosemont, IL, USA). 
The sources of other antibodies were as follows: beta-actin (Sigma-Aldrich Corporation, 
St. Louis, MO, USA) and caspase 3, c-RAF, DGK-α, microtubule-associated protein 
1A/1B-light chain 3 (LC3), and poly (ADP-ribose) polymerase (PARP) (Cell Signaling 
Technology, Inc., Danvers, MA, USA).  
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High-Throughput Drug Screen  
Five hundred TSC2 +/+ MEFs and TSC2-/- MEFs were plated in each well in a 
384-well format (duplicate). After a 24-hour incubation period, a drug screen was 
performed at the Broad Institute (Cambridge, MA) using approximately 4000 compounds 
utilizing the Chemical Biology platform to screen repurposing small molecules and the 
Cancer Target Discovery and Development (CDT2) libraries. Cells were either treated 
with CQ (5 µM) or with vehicle control (H2O) to identify agents that synergize with 
autophagy inhibition to selectively inhibit proliferation of TSC2-deficient cells. Cell 
viability was assessed 48 hours post-treatment. Results were normalized to the plate 
background variability and to a positive control (staurosporine).  
 
CTG Cell Proliferation Assay 
For the CellTiter-Glo (CTG) assay, TSC2-deficient cells and wild-type cells (DJK 
MEFs) were plated in white tissue culture-treated 96-well plates at a density of 1500 
cells/mL in a volume of 50 µL per well. Cells in the first row were treated with dimethyl 
sulfoxide (DMSO) vehicle at the same concentration as the highest concentration of drug 
(20 μM). Cells in the second row were treated with chloroquine at 5 μM. In rows 3-6, 
cells were treated in increasing doses (1 μM, 5 μM, 10 μM, and 20 μM) of ritanserin 
alone. In rows 7-10, cells were treated in increasing doses (1 μM, 5 μM, 10 μM, and 20 
μM) of ritanserin in combination with chloroquine at 5 μM. Cells were treated for 24-72 
hours at 37 °C under 5% CO2. At 24, 48, and 72 hours after treatment, equal parts of the 
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CellTiter-Glo buffer and substrate were prepared, and 100 μL of the resulting solution 
(CellTiter-Glo solution) was added to each well. Plates were shaken in an orbital shaker 
for about 120 seconds and then read using a standard BioTek microplate reader (OD 540 
nm; BioTek Instruments, Inc., Winooski, VT, USA). 
 
Crystal Violet Assay 
Cells were seeded at a density of 1500 cells/well in clear 96-well plates in a 
volume of 50 µL per well. Cells were treated in the same manner as in the CTG assay, 
including the same concentrations. After treatment for 24, 48, or 72 hours, cells were 
fixed with 10% formalin at 200 µL per well for 10 minutes, stained with 0.05% crystal 
violet at 200 µL per well for 20 minutes, washed twice (with distilled water), and then air 
dried. Crystal violet was solubilized with 100 mL of methanol, and the solutions were 
measured with a standard Biotek microplate reader (OD 540 nm; BioTek Instruments, 
Inc.). 
 
Cell Counts 
DJK MEFs were plated in 12-well plates at a density of 8 x 105 cells (+/+) or 4 x 
105 cells (-/-) using 2 mL of DMEM per well. After a 24-hour incubation period, cells 
were treated with DMSO, CQ (5 μM), ritanserin (20 μM), or combinations of the 
indicated concentrations. After separate incubation periods of 24 and 48 hours, adherent 
cells were washed and detached with 0.5 mL of trypsin. The cells were then collected in 1 
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mL of DMEM, mixed with 10 μL of trypan blue solution, and counted using a cell 
counter (Countless II FL; Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA). 
 
Protein Extraction and Western Blot Analysis 
DJK MEF (4 x 105 -/-, 8 x 105 +/+) cells were treated with either DMSO, staurosporine (2 
μM), CQ (5 μM), ritanserin (20 μM), or a combination of (CQ + Rit). For western blot 
analyses, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (1X) (Cell 
Signaling Technology, Inc.) containing protease and phosphatase inhibitors (Sigma-
Aldrich Corporation). Cells were centrifuged at 12,000 RPM for 15 minutes, and the 
supernatant of the whole cell lysate was collected. A 2 μL volume of sample was mixed 
with 8 μL of water and 190 μL of Bradford reagent (1:10 dilution) (Sigma-Aldrich 
Corporation) in a 96-well plate and read on a Biotek microplate reader (OD 540 nm; 
BioTek Instruments, Inc.) to measure actual protein amount. Protein extracts were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and then blotted onto a polyvinylidene difluoride (PVDF) membrane. A 30 μL volume of 
sample was used per lane. Blots were blocked in 30% bovine serum albumin (BSA), 
incubated with primary then secondary antibodies, and visualized for chemiluminescence 
using SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher 
Scientific, Waltham, MA, USA) on SynGene G:BOX gel documenting system (company, 
location). The relative densities of bands were evaluated and normalized with beta-actin 
(Sigma-Aldrich Corporation). The source of antibodies was as follows: cleaved caspase 
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3, LC3, TSC2, phosphorylated S6 (pS6) ribosomal protein, S6 ribosomal protein, DGK-
a, c-RAF, pMEK, and total MEK (Cell Signaling Technology, Inc.). 
  
Apo-ONE Assay 
Apo-ONE assays were performed as directed by the manufacturer (Promega 
Corporation). Wild-type cells (DJK MEFs) were plated on white 96-well plates. A 
quantity of 1500 wild-type and null cells were plated on the same white plate at a density 
of 1500 cells/mL in a volume of 50 μL/well. After a 24-hour incubation period, cells 
were treated with inhibitors at the indicated concentrations for 24 hours at 37 oC under 
5% CO2. Conditions consisted of the negative control dimethyl sulfoxide (DMSO), the 
positive control staurosporine (2 μM), chloroquine (5 μM), ritanserin (20 μM), and the 
combination of chloroquine and ritanserin. Afterward, 100 μL of the prepared caspase 3/7 
reagent was added to each well. The reaction was allowed to proceed at room 
temperature and was then placed on a shaker for 2 minutes. The luminescence was read 
for each well. Data were normalized to the negative control DMSO.  
 
Computational Methods and Determination of Synergy 
Synergy was calculated using the Loewe Additivity approach. This method was 
based on finding the concentration of each drug (CQ and Rit) that produces the same 
quantitative effect. In this case, the concentration was IC50, the inhibitor concentration 
for 50% reduction in response. TSC2-deficient cells and wild-type cells (DJK MEFs) 
were plated onto six white tissue culture-treated, 96-well plates at a density of 1500 
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cells/mL in a volume of 50 µL per well. After a 24-hour incubation period, cells were 
treated with the drug (either CQ or Rit) in nine different doses (1‒50 μM). This 
representation made it clear that when drug A was present at dose a, the quantity of drug 
B needed to reach the specified level was zero, and the presence of drug B reduced the 
need for drug A in a quantity predicted by the model (Foucquier, Guedj, 2015). 
 
Statistical Analysis 
Normally distributed data were analyzed for statistical significance with Student’s 
unpaired t-test, and multiple comparisons were made with one-way and two-way analysis 
of variance (ANOVA) tests with Bonferroni correction. All results for in vitro studies 
were presented as the mean ± 95% standard deviation (SD) (Graph Prism version 6; 
GraphPad Software, www.graphpad.com). Statistical significance was defined as p < 
0.05.  
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RESULTS 
 
Identifying Chloroquine Collaborators Through Small Molecule High-Throughput 
Screening  
To identify molecules that could synergize with chloroquine to selectively induce 
death in TSC2 null cells, a high-throughput drug screen with TSC2 -/- MEFs was 
conducted. The high-throughput drug screen was performed at the Broad Institute of MIT 
and Harvard (Cambridge, MA, USA) according to the plating timeline in Figure 4A. The 
compound library was composed of FDA- approved compounds that were available for 
repurposing to different diseases. Compound “hits” where selected based on two criteria: 
(1) ATP levels needed to be reduced close to the levels of the positive control 
(staurosporine), and (2) compounds had to inhibit proliferation of TSC2-deficient cells 
while not impacting the proliferation of TSC2-expressing cells. 
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Figure 4. Therapeutic targeting of tuberous sclerosis and LAM using high-throughput screening. (A) 
Diagram shows plating timeline at the Broad Institute (Cambridge, MA, USA), including doses of CQ, 
DMSO, staurosporine, and library drug.  
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Figure 4. Therapeutic targeting of tuberous sclerosis and LAM using high-throughput screening. (B) 
Table presents top 21 hits that matched certain criteria. Columns indicate the four cells lines that were used 
(TSC+/+ Veh, TSC2-/-Veh, TSC2+/+CQ, TSC2-/-CQ) with appropriate scores for each hit.  
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Figure 4. Therapeutic targeting of tuberous sclerosis and LAM using high-throughput screening. (C) 
Dose-response curves of ritanserin are plotted with all four cell lines overlapped. Doses are measured in log 
concentration, and cell activity is measured as a percentage of the positive control (staurosporine). (D) 
Dose-response curves of ritanserin are plotted with all four cell lines separated. ATP = adenosine 
triphosphate; CQ = chloroquine; DMSO = Dimethyl Sulfoxide; LAM =  Lymphangioleiomyomatosis; TSC 
= Tuberous Sclerosis Complex; Veh = Vehicle  
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The Broad Repurposing library contained comprehensive annotations for 2350 
FDA-approved drugs, 1600 drugs at phases 1-3 of clinical development, and 1582 
preclinical compounds. Five hundred TSC2-/- and TSC2+/+ DJK MEFs were plated on 
each well of a 384-well plate in duplicate, in the presence of chloroquine (5 μM) or 
vehicle control (Figure 4A). After a 16-hour incubation period, a 100 nL volume of each 
compound or positive control (Staurosporine; 2 μM) was pinned in duplicate using an 
automated pinning tool (CyBio Vario, analytikjena, California). After a 48-hour 
incubation period, cell viability was monitored using an ATP-level assay (CellTiter-Glo 
assay) to measure viability in a high-throughput format. A table was created) indicating 
the 21 best hits considering their overall effect on the cell viability of TSC2-/- CQ 
compared with the vehicle controls and the cell viability of TSC2 +/+ CQ (Figure 4B). 
Compounds were chosen that showed selective inhibition of proliferation of TSC2-/- 
MEFs in the presence of CQ. The drug screen results were organized on a scale of -100 to 
100, with -100 being the positive control (staurosporine). Compounds were chosen that 
showed no effect in viability of TSC2+/+ cells (with or without CQ) and no effect in 
viability of TSC2-/- MEFs treated with vehicle control, relative to the positive control. 
Compounds that selectively inhibited the viability of TSC2-/- MEFs in the presence of 
CQ (negative values in Figure 4B) were selected for further validation. The screen 
indicated that the drug ritanserin, a known SSRI, was the top hit, in that it was 
significantly more effective than staurosporine, a known apoptotic inducer, at causing a 
cytotoxic effect in TSC2 -/- CQ cells.  
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 Dose-response curves were calculated for every hit that was found. Data were 
normalized to the positive control. Z-scores were calculated to identify the number of 
standard deviations from the mean for ATP levels of each compound compared with 
untreated cells and the positive control. Figure 4D shows individual growth curves with 
increasing doses of ritanserin in the four conditions (TSC2+/+ Veh, TSC2+/+ CQ, TSC2-
/- Veh, TSC2-/-CQ). Figure 4C shows all four growth curves together. Overall, these 
curves indicated a decrease in cell viability based on an increasing dose-dependent 
manner in cells treated with CQ. This effect was exacerbated in the TSC-/- CQ cells, with 
the curve having a steep drop at higher concentrations. This result indicated that 
ritanserin is worth investigating further as a possible cytotoxic agent against TSC.  
 
Ritanserin in Combination with Chloroquine Shows Selectivity for Decreasing Cell 
Viability in TSC2 Null Cells  
 DJK MEFs and TFF-4HT/ethanol cells were chosen as the TSC2 cell models to 
evaluate the efficacy of ritanserin as a possible cytotoxic agent. The effects of ritanserin 
and chloroquine on cell viability were determined by setting up proliferation assays in 
white 96-well plates as shown in Figure 5A. At the time of plating, cells were pretreated 
with 5 μM of CQ according to the drug screen protocol at the Broad Institute. After a 24-
hour incubation period, cells were treated with DMSO, CQ alone, four different doses of 
ritanserin alone, or four different doses of ritanserin in combination with chloroquine at 5 
μM.  Chloroquine, a lysosomotropic agent, inhibits lysosomal function by accumulating 
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in the lysosome and increasing the pH of the acidic organelle (Figure 5F). The specific 
function of Ritanserin is still unknown in our study.  
 
Figure 3. Ritanserin in combination with chloroquine is selective against TSC2 null cells. (A) Diagram 
shows visual representation of the experimental plate setup for the two proliferation assays (CellTiter-Glo 
and crystal violet). (B) Growth curves show time course (24, 46, and 72 hours) of drug treatment (CQ 5 
μM, Rit 20 μM) on DJK MEFs using CTG. 
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Figure 4. Ritanserin in combination with chloroquine is selective against TSC2 null cells. (C) Bar 
graph shows 24-hour time point comparing cell viability between different doses and different cell lines 
(DJK MEFs) using CTG. (D) Bar graph shows 48-hour time point using CTG. (E) Bar graph shows 72-
hour time point focused on ritanserin at a 20 μM dose using CTG. (F) Molecular structures are illustrated 
for ritanserin (top) and chloroquine (bottom). 
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Figure 5. Ritanserin in combination with chloroquine is selective against TSC2 null cells. (G) Bar 
graph shows 48-hour time point comparing cell viability between different doses and different cell lines 
(TSC2 KO, TSC2 WT) using crystal violet assay. (H) Bar graph shows 48-hour time point focused on 
ritanserin at a 20 μM dose using crystal violet assay. (I) Bar graph shows 72-hour time point using 
crystal violet assay. (J) Bar graph shows 72-hour time point focused on ritanserin at a 10 μM dose using 
crystal violet assay. CQ = chloroquine; CTG = Cell Titer Glo; DJK MEFs = David Kwiatkowski Mouse 
Embryonic Fibroblasts; DMSO = Dimethyl Sulfoxide; FC = Fold Change; KO = Knock Out; Rit = 
Ritanserin; TFF = TSC2flox/flox-Rosa26-CreERT2 ; TSC = Tuberous Sclerosis Complex; WT = Wild Type  
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Cells were treated with varying concentrations of ritanserin alone (1 μM, 5 μM, 
10 μM, or 20 μM) or varying conditions of (CQ + ritanserin). Cell viability was 
determined using 100 μL of CellTiter-Glo solution per well and measuring ATP levels. 
Cell viability was recorded every 24 hours for 3 days. Concentration-dependent decreases 
were observed in TSC2 null cells exposed to a combination of CQ and ritanserin, but 
similar decreases in cell viability were not seen in the TSC2 wild-type cells (Figure 
5C,D,E). Cell death by the combination of ritanserin and CQ was quick. At high 
concentrations of Rit (20 μM), cell death in TSC2 null cells at 24 hours was already 
decreased by 46% compared with 17% reduction in the wild-type cells (Figure 5C). At 48 
hours, the decrease in cell viability continued. At moderate concentrations of ritanserin 
(10 μM) in combination with CQ (5 μM), cell viability in the TSC2 null cells decreased 
by about 53%, and cell viability of TSC2 wild-type cells decreased by about 20% (Figure 
5D). At a higher concentration of ritanserin (20 μM) in combination with CQ (5 μM), the 
decrease in cell viability in the TSC2 null cells was about 71%, whereas the decrease in 
cell viability of the TSC2 wild-type cells was about 45% (Figure 5D). Although the 
combination of drugs seemed to have a mild effect on the +/+ cells, the effect was much 
greater in the -/- cells. At 72 hours, the highest dosage of ritanserin (20 μM) in 
combination with CQ (5 μM) resulted in a decrease in cell viability of 80% (Figure 5E). 
In comparison with the null cells, the wild-type cells (at 72 hours) with the same high-
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dosage combination showed a decrease in cell viability of only 33%.  The 53% difference 
in cell viability change between the cell lines confirmed that in combination, ritanserin 
and chloroquine are effective in selectively killing cells TSC2 knockdown.   
In order to confirm these results, the same experiment was repeated using the TFF 
cells. These MEFs were isolated from TSC2flox/flox-Rosa26-CreERT2 embryos at embryonic 
days 13-14 and were treated with 4-hydroxytamoxifen (2 μM for 1 week) (Ogorek, Lam, 
Khabibullin, Liu, Henske, et al., 2018). Cells treated with ethanol were used as controls 
(TSC2 WT MEFs). A crystal violet assay was performed using the TFF cells. Like the 
CTG assay, the crystal violet assay was also used to determine the viability of culture 
cells. A quantity of 1500 cells of both the WT and KO cells were plated in clear 96-well 
plates. The cells were treated with varying conditions of ritanserin alone (1 μM, 5 μM, 10 
μM, or 20 μM) or varying conditions of (CQ + ritanserin) (Figure 5A). Cell viability was 
measured at three separate time points (24 hours, 48 hours, and 72 hours) by fixing cells 
using 200 μL of 10% formalin (10 minutes), 20 μL of 0.05% crystal violet solution (20 
minutes), and 200 μL of methanol (5 minutes) before reading the absorbance at 540 nm 
on the Biotek microplate reader (BioTek, Instruments, Inc.). At 24 hours, the drugs had 
very little effect on the growth of the cells, unlike the DJK MEFs that quickly began to 
show signs of cell death. At 48 hours (Figure 5G), the drug ritanserin (20 μM) had a 
strong cytotoxic effect on its own, causing a 75% reduction in cell viability of the TSC2 
KO cells compared with a 47% reduction of the TSC2 WT cells. The combination of 
chloroquine and ritanserin (20 μM) at 48 hours was a bit more effective in that it killed 
80% of TSC2 KO cells and 70% of TSC2 WT cells (Figure 5H). The 10 μM dose of 
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ritanserin alone, at 48 hours, had no effect on either cell line, whereas the combination 
seemed to decrease cell viability by about 30% in the TSC2 WT cells and 40% in the 
TSC2 KO cells (Figure 5G). At 72 hours (Figure 5J), the combination of chloroquine and 
ritanserin was finally showing an ability to selectively kill off the KO cells significantly 
more than the WT cells. Again, the 20 μM dose of ritanserin, either alone or in 
combination, was very cytotoxic to the cells, but the 10 μM dose showed the possibility 
of synergy and selectivity against the TSC2 null cells. Ritanserin alone (10 μM) had no 
effect on the cells, but ritanserin in combination with CQ had a significant cytotoxic 
effect. The TSC2 WT cells had a 40% decrease in cell viability compared with the TSC2 
KO cells, which had an 85% decrease in cell viability. This proved that the drug 
combination is selective in causing cell death in the TSC2 KO cells and minimal cell 
death in the TSC2 WT cells.  
 
Ritanserin in Combination With Chloroquine Shows Signs of Synergy in Relation to 
Inhibiting TSC2 Null Cell Proliferation  
 When two compounds are in synergy with each other, there is a greater effect for 
the drugs in combination than for the simple additive effect expected from the knowledge 
of the effect of each drug individually. For this study, the Loewe Additivity model was 
used to analyze the potential synergy between ritanserin and chloroquine. The Loewe 
Additivity model rests on two main assumptions:  
1. For a given effect, dose a of drug A is equivalent to dose b of drug B, and 
reciprocally (Foucquier & Guedj, 2015). 
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2. Dose ba can be added to any other dose b of drug B to give the additive effect of 
the combination (Foucquier & Guedj, 2015).  
 
 
Figure 6. Ritanserin in combination with chloroquine is synergistic against TSC2 null cells. (A) Bar 
graph shows cell viability data using CTG for increasing doses of CQ alone after 48-hour treatment. (B) 
Bar graph shows cell viability data using CTG for increasing doses of Rit alone after 48-hour treatment. All 
data is normalized to DMSO (negative control) and measured using fold change (FC).  
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Figure 7. Ritanserin in combination with chloroquine is synergistic against TSC2 null cells. (C) Plot 
depicts a graphical representation of the Loewe Additivity method. Axes represent the increasing doses of 
CQ and Rit that were measured in (A) and (B). Red circle represents the IC50 of ritanserin. Blue circle 
represents the IC50 of chloroquine. Orange star indicates the ideal combination dose that represents 
synergy. (D) Plot shows the calculation of the IC50 value of CQ. (E) Plot shows the calculation of the IC50 
value of Rit.  
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Figure 8. Ritanserin in combination with chloroquine is synergistic against TSC2 null cells. (F) Bar 
graph shows cell viability using CTG at 48 hours of treatment with Rit and CQ combinations. (G) Example 
shows mathematical approach to calculate synergy in the Loewe Additivity method. A = Rit; B = CQ; Ci,x = 
dose of Rit required for combination effect; CI = Combination Index; CQ = Chloroquine; CTG = Cell Titer 
Glo; ICx,i = Half Maximal Inhibitory Concentration of Rit; IC50 = Half Maximal Inhibitory Concentration; 
Rit = Ritanserin; TSC = Tuberous Sclerosis Complex   
 
The Loewe Additivity approach uses a dose-effect-based strategy to find what amount or 
concentration of each drug produces the same quantitative effect.  
The dose-effect curves of both ritanserin and chloroquine were obtained by 
plating DJK MEFs on white 96-well plates. After a 24-hour incubation period, cells were 
treated on separate plates with increasing concentrations (5-50 μM) of either ritanserin or 
chloroquine. Cell viability was measured at 48 hours using a CellTiter-Glo assay (Figure 
6A, B). Concentration-dependent decreases were observed in the viability in both cells 
treated with chloroquine and ritanserin. At higher concentrations (25-50 μM), ritanserin 
had a much larger effect in decreasing cell viability compared with the same 
concentrations of chloroquine. Based on the cell viability data, the IC50 values were 
determined to be 31 μM for CQ and 22 μM for ritanserin (Figure 6D, E).  
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 The Loewe Additivity model can be represented with algebraic analysis using the 
equation: CI = $% + '( , where CI is the combination index and a & b are the doses that in 
combination give a reduction in cell viability, in our case 50%. A value of CI < 1 
indicates that the doses a and b giving rise to a certain effect when combined are lower 
than the expected doses from additivity and can therefore be confirmed as synergy. On 
the other hand, a value of CI > 1 indicates that the doses a and b producing a given effect 
when combined are higher than the expected doses from additivity and can therefore be 
interpreted as antagonistic.  
Following the Loew Additivity model, an isobologram was created with the 
ritanserin IC50 (22 μM) on the x-axis and the chloroquine IC50 (31 μM) on the y-axis 
(Figure 6C). The isobologram represents a graphical analysis of the expected values for 
50% cell viability. The down-sloping trendline on the graph is the line of additivity. 
Every point on the line represents the predicted doses that are needed from CQ and Rit to 
attain a decrease in 50% cell viability. The graph indicates that when drug A is present at 
dose a, the quantity of drug B needed to reach a certain specified level (in this case IC50) 
is zero, and that the presence of drug B reduces the overall need for drug A in a quantity 
predicted by the isobologram  The principle states that any experimental point below the 
line (CI < 1) is considered synergy, any point on the line (CI = 0) is an additive effect, 
and any point above the line (CI > 1) is an antagonistic effect.  
  To calculate the synergy between chloroquine and ritanserin, a procedure was 
undertaken in which DJK MEFs (both +/+ and -/-) were plated into 96-well plates. After 
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a 24-hour incubation period, the cells were treated with either DMSO, CQ (5 μM), 
ritanserin alone (1 μM, 5 μM, 10 μM, or 20 μM), or a combination of CQ (5 μM) and 
ritanserin (1 μM, 5 μM, 10 μM, or 20 μM). The CellTiter-Glo assay was used to measure 
cell viability at 24 hours, 48 hours, and 72 hours. The results at 48 hours were examined 
(Figure 6F), mainly because the other synergy experiments had been analyzed at this time 
period (Figures 6A-E). The cell viability for TSC2 null cells at a dose of CQ = 5 μM and 
Rit = 10 μM was 0.476 (highlighted by a red frame in Figure 6F). This value indicated 
that after 48 hours at this combination dose of 5 μM CQ and 10 μM Rit, the cell viability 
decreased to about 48%.  
This dosage, or new experimental point (a, b), was applied to the isobologram in 
Figure 6C and corresponded to the doses that were actually needed to get a combination 
effect (in this case IC50). An orange star represents the point on the graph in Figure 6C. 
Because the star fell below the line of additivity (dotted blue line) on the graph, synergy 
was implied for this combination. Furthermore, the combination index (CI) was solved 
using the equation 𝐶𝐼 = +,,./+., 	+ +1,./+.,1 (Figure 6G). The values in the numerators (CA,x and 
CB,x) are the doses of CQ and Rit that in combination gave a decrease in cell viability of 
about 50% (5 μM and 10 μM, respectively) (Figure 6F). The values in the denominators 
(ICx,A and ICx,B) are the IC50 values determined for CQ alone and for Rit alone (31 μM and 
22 μM, respectively) (Figure 6 D, E). Using the combination index equation (Figure 6G), 
a value of 0.616 was calculated for CI, which indicated synergy between chloroquine and 
ritanserin (CI < 1). 
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Use of Apo-ONE Assay Shows That the Combination of CQ and Ritanserin Induces 
Apoptotic Levels That Are Higher Than the Positive Control Staurosporine 
 Apoptotic activity was measured by treating DJK MEFs with a combination of 
ritanserin and chloroquine and comparing the results with a known apoptotic inducer, 
staurosporine. Staurosporine has been shown to induce apoptosis through both caspase-
dependent and caspase-independent mechanisms. Therefore, staurosporine worked as a 
good positive control for testing the apoptotic levels of ritanserin and chloroquine. Cells 
that were treated with the combination of ritanserin and chloroquine showed statistically 
significant enhanced caspase 3/7 activity after 24 hours compared with the negative 
control DMSO (41%; p < 0.001) (Figure 7A). Although the apoptotic level of the 
combination was not greater than the level of staurosporine, the high level of 
luminescence in the combination seemed to indicate that it was effective in inducing 
apoptosis. Although staurosporine had more than a 2-fold increase in caspase 3/7 activity 
(compared with DMSO), the combination of ritanserin and chloroquine caused a 1.3-fold 
increase (compared with DMSO) (Figure 7B). The combination drug treatment also 
resulted in a higher level of caspase 3/7 activity compared with treatment by chloroquine 
alone or ritanserin alone. This effect suggests that the combination is essential for the 
induction of key apoptotic markers,
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Figure 9. The combination of ritanserin and chloroquine shows increased levels of caspase 3/7 
activity. (A) Bar graph shows caspase 3/7 assay after 24 hours of treatment with inhibitors as measured by 
luminescence (AU). **p < 0.001. (B) Bar graph shows caspase 3/7 assay after 24 hours of treatment with 
inhibitors. Data are normalized to negative control (DMSO), and fold changes are indicated. (C) Bar graph 
shows caspase 3/7 assay after 24 hours of treatment with inhibitors as measured by luminescence (AU). 
Both DJK MEF cell lines are included for comparison. (D) Bar graph shows caspase 3/7 assay (done in 
triplicate) after 24-hour treatment with inhibitors as measured by luminescence (AU). AU = arbitrary unit; 
CQ = Chloroquine; DMSO = Dimethyl Sulfoxide; TSC = Tuberous Sclerosis Complex.  
	37 
 
such as caspase 3/7. There also appeared to be some selectivity for the appearance of 
apoptotic marker caspase 3/7 in the DJK MEF -/- cells compared with the +/+ cells. With 
the combination drug, luminescence reached over 20000 AU in the TSC2-/- cells 
compared with under 20000 AU in the TSC2+/+ cells (Figure 7C). These data were 
confirmed using triplicates of both TSC2+/+ and TSC2-/- cell lines (Figure 7D). 
In summary, the cell viability and caspase 3/7 induction data supported the 
combination of ritanserin and chloroquine as effective in activating apoptosis and 
inducing cell death in TSC2 null cells. Subsequent work (immunoblotting) needs to be 
performed in order to determine the exact mechanisms of action of ritanserin alone and in 
combination with chloroquine.  
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DISCUSSION 
 
 Tuberous sclerosis complex is a multisystem disease in which inactivation of the 
TSC1 or TSC2 gene leads to mTORC1 hyperactivation (Filippakis, Alesi, Ogorek, 
Nijmeh, Henske, et al., 2017). In the present study, a high-throughput drug screen was 
performed to find drugs that can synergize with the known autophagy inhibitor, 
chloroquine, for the purpose of selectively reducing the cell viability of TSC2 -/- cells 
while keeping the cell viability of TSC2 +/+ cells stable. The results indicated that the 
drug ritanserin, which had been previously shown to be used as a cytotoxic agent against 
glioblastoma and melanoma (Dominguez, Floyd, Xiao, Mullins et al, 2013) works in 
combination with chloroquine to cause the death of TSC2 null cells. Neither drug on its 
own was effective in reducing cell viability, whereas the combination acted to 
significantly decrease the growth of the cancer cells. Although other studies have 
indicated that ritanserin could be disrupting either c-RAF or DGK-a, this study was 
unable to replicate such results.  
 Many studies dealing with TSC and LAM have involved the use of rapamycin or 
inhibitors that are used as single agents. Rapamycin and its analogs decrease the size of 
TSC-associated angiomyolipoma and subependymal giant cell astrocytomas and decrease 
the rate of lung decline in women with TSC-associated and sporadic LAM. 
Unfortunately, these rapalogs tend to only partially decrease tumor size in patients with 
TSC, with most studies demonstrating a 20% to 40% decrease in tumor volume 
(Medvetz, Sun, Li, Khabibullin et al., 2015). Other inhibitors have proven to be effective 
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as single agents, but a monotherapy has many limitations. TSC is a disease that affects 
multiple areas of the body and can manifest itself in many different areas, including 
benign tumors of the brain, heart, kidneys, skin, and other organs that contain giant cells. 
Therefore, drug combinations that can potentially target multiple cancer pathways and 
disrupt cancer cell growth may have potential therapeutic benefits. Furthermore, drug 
combinations may be effective in overcoming the constant drug resistance that cancer 
seems to quickly develop.  
In order to find drugs that can combine with chloroquine to induce tumor cell 
death, this study utilized a high-throughput drug screen. All hits that met the primary 
criteria were noted and retested using 96-well plate proliferation assays (Figure 5A). The 
best hit confirmed through the CellTiter-Glo assays was ritanserin. Based on the CTG 
and crystal violet data using two different cell lines, the combination of ritanserin (10-20 
μM) and CQ (5 μM) was verified to be effective in inducing a selective cytotoxic effect 
against TSC2-/- cells. In the DJK MEFs, a concentration-dependent decrease in TSC2 
null cells exposed to the combination was discovered, with little to no effect on the TSC2 
wild-type cells. After 72 hours of drug treatment at a concentration of 20 μM ritanserin, 
the cell viability of TSC2 +/+ cells was about 20% compared with 77% cell viability in 
the TSC2 -/- cells. This result was confirmed by using TFF cells and measuring cell 
viability through crystal violet instead of CTG. At 72-hour drug treatment, the 
combination of ritanserin (10 μM) and CQ (5 μM) reduced cell viability selectively in 
TSC2 KO cells by 85% compared with a reduced cell viability in TSC2 WT cells of 40%. 
These results helped to validate the high-throughput data and the effectiveness of the 
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combination of ritanserin and CQ in causing a cytotoxic effect in multiple TSC2 
knockdown cell lines.  
Interestingly enough, this study confirmed that the use of ritanserin reduces the 
dose that is needed for chloroquine to be effective, a consequence otherwise known as 
synergy. Based on the Loewe Additivity model, ritanserin and chloroquine were verified 
to synergize to reduce cell viability in TSC2-/-CQ cells. Although there are many models 
that have been used to determine synergy between two compounds, the Loewe Additivity 
model was chosen because it gives a mathematical representation of synergy and 
complements the algebraic analysis with a widely accepted graphical approach. However, 
it is important to consider that there are practical limitations to this analysis. First, the 
model relies on accurately estimated dose-effect curves to support the calculation of the 
effective doses (A and B) for a given effect (Fouqier, Guedj, 2015). The execution of 
multiple cell viability curves at multiple doses can be expensive and computationally 
demanding. In this study, properly developed dose-effect curves allowed for the 
determination of IC50 values and the creation of an accurate isobologram. The second 
issue with the calculation of synergy is the optimization of dose ratios. This suggests that 
the combination therapy is not simply the property of the drugs but could also depend on 
the dose ratio. Because the cells cannot distinguish between a single drug and a 
combination of drugs, the two drugs that are combined at a specified ratio could be seen 
as a third agent with its own dose-effect relation (Chou, 2010). In this study, specific 
doses were tested (Figure 6D), and therefore only one combination (ritanserin 10 μM, CQ 
5 μM) was proved to be in synergy. Further experimentation on subsequent doses could 
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prove that there is a wide array of doses of ritanserin and CQ that can synergize together 
to cause this cytotoxic effect against TSC2 -/-CQ. In this study, the results confirmed 
that, albeit a single dose, the combination of ritanserin (10 μM) and CQ (5 μM) 
synergizes to selectively reduce cell viability in TSC2-/-CQ. Furthermore, this study 
gives the proper methods, using the Loewe Additivity analysis, to determine synergy 
between two compounds.  
The caspase 3/7 assay data showed a significant increase in fold change of the 
apoptotic marker, caspase 3/7, in the combination-treated cells compared with the 
negative control (DMSO), although the increase was still lower than the positive control 
(staurosporine) (Figure 7D). The lack of data in immunoblotting for apoptotic markers 
(cleaved caspase 3, LC3, and cleaved PARP) indicated that it is still unclear exactly what 
role ritanserin or CQ is playing in inducing apoptosis and how this combination is 
affecting the mTORC1 pathway to decrease cell viability. What is known from previous 
studies involving CQ is that it can be an inducer of apoptosis through autophagy 
inhibition. By inhibiting autophagy, CQ can subsequently cause the accumulation of 
unfolded proteins that activate the endoplasmic reticulum (ER) stress pathway leading 
toward apoptosis (Masud, et al., 2016). These results, along with the results of this study, 
indicate that CQ is involved in activating apoptotic markers and therefore can be used as 
an effective target for the treatment of TSC2 and other cancers. Other studies have shown 
that the combination of mTORC1 and autophagy inhibition was more effective than 
either treatment alone in inhibiting the survival of tuberin (TSC2) null cells, the growth 
of TSC2-null xerograph tumors, and the development of spontaneous renal tumors in 
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TSC2+/- mice (Parkhito, Myachina, Morrison, Hindi, et al., 2011). These data, together 
with what is presented in this study, demonstrate that autophagy is a critical component 
of TSC tumorigenesis. 
One of the main focuses in this study, after the selection of ritanserin as the drug 
to test in combination with CQ, was to find the mechanism of action of how ritanserin 
alone, and in combination with CQ, affects the mTOR1 pathway of TSC2 null cells. 
Several studies have indicated possible targets of ritanserin. One study showed that 
ritanserin blocks c-RAF activation, but not B-RAF activation, of established oncogenic 
signaling pathways in live cells (Campbell, Franks, Borne, Shin, Zhang, et al., 2018). 
Loss of c-RAF resulted in tumor regression of aggressive K-RAS-driven cancers with 
reduced systemic toxicity because canonical MAPK signaling is unaffected. These 
researchers (Campbell et al., 2018) suggested that the utility of targeting c-RAF in the 
clinic extends beyond the studies of just lung cancers. Other investigations into the use of 
ritanserin have identified it as an inhibitor of DGK-a. In one study, a fragment of the 
ritanserin compound (RS9022) was found to induce caspase-mediated apoptosis in 
glioblastoma cells and in other cancers but lacked toxicity in non-cancerous cells 
(Dominguez, et al., 2013). In this study, an attempt was made to show by immunoblotting 
that ritanserin can cause the inhibition of c-RAF and DGK-a, and that the combination of 
ritanserin and CQ can induce certain apoptotic markers. Unfortunately, because of human 
error or faulty antibodies, these results were not confirmed, and evidence toward a 
mechanism of action was not obtained. It is clear that ritanserin has an effect on several 
cancer types, including TSC, but the mechanism of action by which this occurs is still 
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uncertain to this date. Ritanserin cellular activity appears to be mediated through the 
blockade of several kinase networks, giving it a broad action against several tumor cell 
types. Ritanserin is likely to continue as an inhibitor of interest because of its multitarget 
system, which could prove to minimize the potential for the development of cancer-
resistant mechanisms.  
The use of drug combinations to target different cancer metabolites has become a 
popular experimental strategy in the constant battle against cancer resistance. This study 
presents a novel therapeutic approach indicating that ritanserin and CQ can synergize to 
selectively inhibit TSC2 null cells while keeping TSC2 WT cells, for the most part, 
intact. Further experimentation with ritanserin may lead to a better understanding of the 
metabolic vulnerabilities of TSC2-deficient cells.  
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